Brief: Cyclo Therapeutics Reports Q4 And FY20 Financial Results
15/03/2021 12:51
March 15 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS
FOURTH
QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS
* CTD HOLDINGS INC - COMPANY EXPECTS TO COMMENCE ENROLLMENT
IN
PIVOTAL PHASE 3 STUDY OF TRAPPSOL(®) CYCLO™ FOR NPC IN Q2 2021
* CTD HOLDINGS INC - IND FILING FOR TRAPPSOL(®) CYCLO™
ALZHEIMER'S
DISEASE PROGRAM ON TRACK FOR H2 2021
* CTD HOLDINGS INC - NPC PIVOTAL PHASE 3 STUDY INTERIM
ANALYSIS
TOPLINE RESULTS EXPECTED IN Q4 2022
Source text for Eikon: ID:nBw9yCfWsa
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug